




RealRate

PHARMACEUTICAL 2015

Mirati Therapeutics Inc
Rank 173 of 274

MIRATI
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Mirati Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Mirati Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 32% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	32,657
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,396
Liabilities, Non-Current	21
Other Assets	326
Other Compr. Net Income	14
Other Expenses	4,851
Other Liabilities	0
Other Net Income	-77
Other Revenues	0
Property and Equipment	496
Research and Development	26,071
Selling, General and Administrative Expense	12,699

Output Variable	Value in 1000 USD
Assets	33,479
Liabilities	5,417
Expenses	43,621
Revenues	0
Stockholders Equity	28,062
Net Income	-43,698
Comprehensive Net Income	-43,691
BaseVar	41,304
ECR before Limited Liability	90%
Economic Capital Ratio	222%